Health TidingsNovo Nordisk Highlights New Semaglutide Data in MASH Ahead of EASL 2026 Novo Nordisk Highlights New Semaglutide Data in MASH Ahead of EASL 2026 Read Post »
GenericsSamsung Bioepis Launches Ustekinumab Biosimilar in Japan With NIPRO Samsung Bioepis Launches Ustekinumab Biosimilar in Japan With NIPRO Read Post »
Clinical TrialsANKTIVA Plus BCG Outperforms Approved NMIBC Therapies in AUA 2026 Analyses ANKTIVA Plus BCG Outperforms Approved NMIBC Therapies in AUA 2026 Analyses Read Post »
Clinical TrialsInnovent’s Dual-Target Antibody IBI3002 Shows Promise in Asthma Innovent’s Dual-Target Antibody IBI3002 Shows Promise in Asthma Read Post »
Health TidingsBayer Files Asundexian in U.S. and Japan After Positive Phase III Stroke Da... Bayer Files Asundexian in U.S. and Japan After Positive Phase III Stroke Da... Read Post »
Mergers & AcquisitionsHansa Licenses IDEFIRIX Rights to SERB in €115 Million Deal Hansa Licenses IDEFIRIX Rights to SERB in €115 Million Deal Read Post »
Clinical TrialsUCB Pushes BIMZELX Ahead of SKYRIZI in Psoriatic Arthritis Showdown UCB Pushes BIMZELX Ahead of SKYRIZI in Psoriatic Arthritis Showdown Read Post »
Mergers & AcquisitionsIncyte Collaborates With Edison Scientific on AI-Driven Drug Discovery Incyte Collaborates With Edison Scientific on AI-Driven Drug Discovery Read Post »
Health TidingsLantern Advances LP-300 Program After FDA Backs HARMONIC Trial Amendments Lantern Advances LP-300 Program After FDA Backs HARMONIC Trial Amendments Read Post »
Clinical TrialsWave Expands Evidence for WVE-006 in Lung and Liver Manifestations of AATD Wave Expands Evidence for WVE-006 in Lung and Liver Manifestations of AATD Read Post »
Health TidingsTakeda Faces $885 Million Jury Verdict in AMITIZA Antitrust Case Takeda Faces $885 Million Jury Verdict in AMITIZA Antitrust Case Read Post »
Clinical TrialsAlterity Pushes ATH434 Toward Phase 3 With New MSA Disease-Modifying Signal... Alterity Pushes ATH434 Toward Phase 3 With New MSA Disease-Modifying Signal... Read Post »
Clinical TrialsBioMarin Sees Biomarker Win Fade Against Clinical Reality in ENERGY 3 Trial BioMarin Sees Biomarker Win Fade Against Clinical Reality in ENERGY 3 Trial Read Post »
Clinical TrialsSanofi Reports Positive Phase 2 Results for Efdoralprin Alfa in AATD Sanofi Reports Positive Phase 2 Results for Efdoralprin Alfa in AATD Read Post »
Health TidingsImmunityBio Expands ANKTIVA Patent Protection in NMIBC Through 2035 ImmunityBio Expands ANKTIVA Patent Protection in NMIBC Through 2035 Read Post »
Health TidingsFDA Prioritizes Review of Bayer’s Sevabertinib for HER2-Mutant NSCLC FDA Prioritizes Review of Bayer’s Sevabertinib for HER2-Mutant NSCLC Read Post »
Health TidingsApnimed’s AD109 Shows Sustained Sleep Apnea Improvements Through 26 Weeks Apnimed’s AD109 Shows Sustained Sleep Apnea Improvements Through 26 Weeks Read Post »
New Drug ApprovalJapan Expands GSK’s Arexvy Approval to At-Risk Adults Aged 18–49 Japan Expands GSK’s Arexvy Approval to At-Risk Adults Aged 18–49 Read Post »
Health TidingsFDA Accepts Viatris NDA for Fast-Acting Meloxicam in Acute Pain FDA Accepts Viatris NDA for Fast-Acting Meloxicam in Acute Pain Read Post »
Clinical TrialsMerck’s Sac-TMT Shows Survival Benefit in Advanced Endometrial Cancer Merck’s Sac-TMT Shows Survival Benefit in Advanced Endometrial Cancer Read Post »
New Drug ApprovalBoehringer Ingelheim Secures Japan Approval for JASCAYD in Pulmonary Fibros... Boehringer Ingelheim Secures Japan Approval for JASCAYD in Pulmonary Fibros... Read Post »
Mergers & AcquisitionsRegeneron and Parabilis Partner to Develop Antibody-Helicon Conjugates Regeneron and Parabilis Partner to Develop Antibody-Helicon Conjugates Read Post »
ResearchTeva Highlights the Unseen Psychological Toll of Tardive Dyskinesia Teva Highlights the Unseen Psychological Toll of Tardive Dyskinesia Read Post »
New Drug ApprovalFDA Approves AstraZeneca’s Baxfendy, an Aldosterone-Targeting Therapy... FDA Approves AstraZeneca’s Baxfendy, an Aldosterone-Targeting Therapy... Read Post »
Clinical TrialsRalinepag Improved Outcomes in Phase III Pulmonary Hypertension Study Ralinepag Improved Outcomes in Phase III Pulmonary Hypertension Study Read Post »
Health Tidings Mergers & AcquisitionsImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG for Bladder Canc... ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG for Bladder Canc... Read Post »
Clinical TrialsNovartis Shows Improved PSA Responses With Pluvicto in Phase III mHSPC Tria... Novartis Shows Improved PSA Responses With Pluvicto in Phase III mHSPC Tria... Read Post »
Clinical TrialsFDA Clears United Therapeutics’ UHeart Trial in End-Stage Heart Failure FDA Clears United Therapeutics’ UHeart Trial in End-Stage Heart Failure Read Post »
ResearchWhat Is Hantavirus? Understanding Its Spread, Structure, Symptoms, and Risk... What Is Hantavirus? Understanding Its Spread, Structure, Symptoms, and Risk... Read Post »
ResearchNIH-Funded Study Finds Testosterone May Suppress Glioblastoma Growth in Men NIH-Funded Study Finds Testosterone May Suppress Glioblastoma Growth in Men Read Post »
ResearchNIH-Funded Nature Study Finds Orforglipron Suppresses Pleasure-Driven Eatin... NIH-Funded Nature Study Finds Orforglipron Suppresses Pleasure-Driven Eatin... Read Post »
Clinical TrialsRegeneron Continues Melanoma Development After Phase 3 Trial Miss Regeneron Continues Melanoma Development After Phase 3 Trial Miss Read Post »
New Drug ApprovalFDA Approves Tecentriq as First ctDNA-Guided Therapy for Bladder Cancer FDA Approves Tecentriq as First ctDNA-Guided Therapy for Bladder Cancer Read Post »
New Drug ApprovalMHRA Approves Vyjuvek for Dystrophic Epidermolysis Bullosa MHRA Approves Vyjuvek for Dystrophic Epidermolysis Bullosa Read Post »
New Drug ApprovalFDA Approves Enhertu After Positive DESTINY-Breast Phase III Results FDA Approves Enhertu After Positive DESTINY-Breast Phase III Results Read Post »
GenericsAlteogen Secures Korean Approval for EYZANFY in Retinal Diseases Alteogen Secures Korean Approval for EYZANFY in Retinal Diseases Read Post »
GenericsApotex Launches Generic Ozempic Equivalent Apo-Semaglutide in Canada Apotex Launches Generic Ozempic Equivalent Apo-Semaglutide in Canada Read Post »
GenericsSandoz Wins EU Approval for Bysumlog and Dazparda Biosimilar Insulins Sandoz Wins EU Approval for Bysumlog and Dazparda Biosimilar Insulins Read Post »
Clinical TrialsXPro™ Shows Cognitive and Biomarker Benefits in Phase 2 Alzheimer’s Tri... XPro™ Shows Cognitive and Biomarker Benefits in Phase 2 Alzheimer’s Tri... Read Post »
Clinical TrialsPalvella Reports Phase 2 Data Supporting QTORIN in Rare Vascular Disorder Palvella Reports Phase 2 Data Supporting QTORIN in Rare Vascular Disorder Read Post »
Health TidingsAstellas Secures China NDA Acceptance and Priority Review for IZERVAY in Ge... Astellas Secures China NDA Acceptance and Priority Review for IZERVAY in Ge... Read Post »
Clinical TrialsAstraZeneca’s VOLGA Trial Shows Perioperative Imfinzi Plus Enfortumab Ved... AstraZeneca’s VOLGA Trial Shows Perioperative Imfinzi Plus Enfortumab Ved... Read Post »
Health TidingsAstellas Seeks Japan Approval for PADCEV-Keytruda Perioperative Regimen Astellas Seeks Japan Approval for PADCEV-Keytruda Perioperative Regimen Read Post »
Health TidingsAardvark ARD-101 Program Placed on Full FDA Clinical Hold in Prader-Willi S... Aardvark ARD-101 Program Placed on Full FDA Clinical Hold in Prader-Willi S... Read Post »
Health TidingsNICE Approves AstraZeneca’s Durvalumab for Aggressive Stomach Cancer NICE Approves AstraZeneca’s Durvalumab for Aggressive Stomach Cancer Read Post »
Health Tidings Mergers & AcquisitionsEli Lilly and UNICEF USA Strengthen Childhood NCD Care in LMICs Eli Lilly and UNICEF USA Strengthen Childhood NCD Care in LMICs Read Post »
Health TidingsChugai and Nippon Shinyaku Seek Japan Approval for Gazyva in Nephrotic Synd... Chugai and Nippon Shinyaku Seek Japan Approval for Gazyva in Nephrotic Synd... Read Post »
Health TidingsIpsen Presents Phase II LANTIC Data for Corabotase in Glabellar Lines at SC... Ipsen Presents Phase II LANTIC Data for Corabotase in Glabellar Lines at SC... Read Post »
Clinical TrialsBiogen’s Diranersen Falls Short on Primary Goal Yet Signals a Breakthroug... Biogen’s Diranersen Falls Short on Primary Goal Yet Signals a Breakthroug... Read Post »
Clinical TrialsEyePoint Confirms Favorable Safety Profile for DURAVYU in Phase 3 Wet AMD T... EyePoint Confirms Favorable Safety Profile for DURAVYU in Phase 3 Wet AMD T... Read Post »
